Targets › BDNF
2 programs from 2 companies in 2 trials: 2 Phase 1; Neurology; next expected readout Jul 2028.
Important signaling molecule that activates signaling cascades downstream of NTRK2. During development, promotes the survival and differentiation of selected neuronal populations of the peripheral and central nervous systems. (UniProt, P23560)
Open in Phaseline: the race on BDNF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Mark Tuszynski | AAV2-BDNF AAV2-mediated gene therapy expressing human BDNF | BDNF | Phase 1 | Alzheimer's Disease | Jul 2028 |
| BnH Research | BnH-015B GluN2B-selective NMDA receptor positive allosteric modulator; regulates BDNF/TRKβ and micr | GRIN2B, BDNF, NTRK2 | Phase 1 | Alzheimer Disease | – |
Alzheimer's Disease (1) Alzheimer Disease (1)
other (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.